Clinical Trial

A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration

Name: A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration — clinical trial record (NCT07718165)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a first-in-human (FIH), multicenter, open-label, phase I study of ABSK211 in participants with advanced solid tumors to evaluate safety, tolerability, PK and optimize the dosage.

Trial Details

NCT Number	NCT07718165
Lead Sponsor	Abbisko Therapeutics Co, Ltd
Conditions	Solid Tumor (Phase I)
Enrollment	247 participants
Start Date	2026-09-01
Primary Completion	2029-12-30 (estimated)
Study Completion	2030-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-21